Investment Trends - Infrastructure investment growth has declined significantly, with a drop of 2.6 percentage points compared to the recent peak in March, and a broader decline of 4.2 percentage points in general infrastructure investment growth[1] - Fixed asset investment growth fell to 1.6% in July, the lowest since October 2020, while infrastructure investment growth decreased to 3.2%[2] Government Support - Despite the decline in investment growth, government funding support for infrastructure has increased, with local governments issuing 3.5 trillion yuan in new special bonds and ultra-long-term treasury bonds in the first seven months, compared to 2.2 trillion yuan in the same period last year[1] - A funding gap of 616.8 billion yuan is expected in the remaining government bond issuance from August to December compared to last year, prompting predictions of additional fiscal support of 0.5 to 1.0 trillion yuan by the end of September[1][21] Sector Performance - The rapid slowdown in investment growth in public facilities management and ecological environment sectors is a major factor in the overall decline, with public facilities management dropping from 4.9% in April to 0.5% in July, and ecological environment investment falling from 8.5% to -5.4%[4] - Transportation, storage, and postal services showed relatively stable investment growth, with a slight decline in July attributed to extreme weather conditions[6] Future Outlook - Infrastructure investment growth is expected to rebound to 4.5% for the year, up from 3.2% in the first seven months, aided by the low base effect from the previous year and ongoing major projects[29] - The anticipated increase in government bond issuance and new policy financial tools are expected to support infrastructure investment in the latter half of the year[21][29]

浦银国际研究 公司研究 | 医药行业 荣昌生物（9995.HK/688331.CH）：BD 交易 提振现金状况，全年预计减亏明显 公司 2Q25 继续延续此前的减亏趋势，全年有望实现约 50% YoY 减亏。 维持"持有"评级，上调目标价至港股 65 港元、A 股人民币 85 元。 ● 2Q25 年收入大致符合预期，归母净利润好于预期；全年有望实现约 50%幅度减亏：公司 2Q25 年实现收入人民币 5.66 亿元（+38.3% YoY， +7.6% QoQ），主要由 RC18、RC48 产品收入贡献，大致符合我们预期和 VA（Visible Alpha）一致预期。归母净亏损进一步缩窄至 1.95 亿元（- 54.7% YoY, -23.1% QoQ），好于我们和 VA 一致预期，主要由于毛利率好 于预期及研发费用略低于预期。毛利率为 85.5% (+9.3 ppts YoY, +2.2 ppts QoQ)，同比环比均提升明显。研发费用为 3.18 亿元，同比环比均呈下 降态势（-33.0% YoY, -3.2% QoQ）。此外，销售费用为 2.75 亿元，对应销 售费用率为 48.6%，占比较 2Q24 有 ...

浦银国际研究 公司研究 | 互联网行业 阿里巴巴（9988.HK/BABA.US）：战略架构 调整，云业务处于上行通道 业绩不及市场预期：公司 FY26Q1 收入人民币 2,477 亿元，同比增长 2%，低于市场预期 2%；若剔除大润发和银泰外，收入同比增长 10%； 调整后净利润为 335 亿元，同比下降 18%，主要由于淘宝闪购业务的 相关投入。调整后净利率为 13.5%，去年同期为 16.7%。公司将业务分 部重新划分为四大板块，包括阿里巴巴中国电商集团（包含原淘天、 饿了么、飞猪）、阿里国际数字商业集团、云智能集团以及其他（包含 原菜鸟、高德、大文娱）。 CMR 预计维持较高增速，即时零售对短期利润带来压力：FY26Q1 中 国电商收入同比增长 10%至 1，401 亿元，其中客户管理收入（CMR） 同比增长 10%，主要由 take rate 提升所带动，包括基础软件服务费和 "全站推"渗透率提升。公司表示未来几个季度，CMR 将保持和过去 两个季度的较高增速。即时零售收入同比增长 12%，主要得益于于 4 月底推出的淘宝闪购的订单增量。闪购带动电商收益明显：流量上涨 带来广告和 CMR 的提升（在 ...

浦银国际研究 公司研究 | 医药行业 RMB17.4 RMB23.1 RMB27.2 RMB29.4 17. 4 19. 4 21. 4 23. 4 25. 4 27. 4 29. 4 图表 1：盈利预测和财务指标 | 人民币百万元 | 2023 | 2024 | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入 | 1,209 | 806 | 1,085 | 1,330 | 1,598 | | 同比增速（%） | 0.6% | -33.3% | 34.7% | 22.5% | 20.2% | | 归母净利润 | 278 | 125 | 261 | 329 | 420 | | 同比增速（%） | -9.7% | -55.0% | 109.0% | 26.1% | 27.4% | | PE（X）- A 股 | 31.9 | 70.0 | 33.9 | 26.9 | 21.1 | | PE（X）- 港股 | 20.7 | 45.3 | 22.0 | 17.4 | 13.7 | | 资料来源：公司报告、浦银国际 | | | | ...

Investment Rating - The report maintains a "Buy" rating for Meituan, with a target price adjusted to HKD 120, indicating a potential upside of 17% from the current price of HKD 102.7 [4][7][20]. Core Views - The report highlights that Meituan's revenue for Q2 2025 grew by 11.7% year-on-year to RMB 91.8 billion, which was below market expectations by 2.0%. The gross margin decreased by 8.1 percentage points to 33.1% due to increased rider subsidies and overseas business costs [2][3]. - The competitive landscape in the food delivery industry remains intense, with expectations of increased losses in Q3 2025. The core local business revenue grew by 7.7% year-on-year, significantly lower than market expectations, and operating profit dropped by 76% to RMB 3.7 billion [3]. - Meituan is focusing on enhancing its user experience (UE) and operational efficiency, which is expected to strengthen its competitive position despite the ongoing market challenges. The report anticipates that losses will improve in Q4 2025 as industry subsidies decrease [3][4]. Financial Summary - For FY25E, the report projects revenue of RMB 368.1 billion and a net profit loss of RMB 12.8 billion. The adjusted net profit is expected to be RMB -7.2 billion, with a significant recovery anticipated in FY26E [6][11]. - The report provides a detailed financial forecast, indicating a revenue increase to RMB 469.7 billion by FY27E, with a gradual recovery in operating profit and net profit margins over the forecast period [6][11]. Business Strategy - Meituan is strategically shifting its focus from underperforming segments like Meituan Youxuan to other new retail businesses, while also expanding its international presence through Keeta, which has shown strong growth in order volume and transaction value [4][3]. - The report emphasizes the importance of maintaining competitive pricing and high-quality product offerings to cater to diverse consumer needs, which is crucial for sustaining market share in a highly competitive environment [3][4].

Investment Rating - The report maintains a "Buy" rating for the company, Li Auto (LI.US/2015.HK), with a target price of $26.4, representing a potential upside of 17% for the US stock and a target price of HKD 102.6, representing a potential upside of 16% for the HK stock [2][4][6]. Core Insights - The report highlights that while there are fluctuations in the sales guidance for the third quarter, the gross margin is expected to remain stable. The company is actively adjusting its sales strategies to enhance sales performance, and the upcoming launch of the i6 model is anticipated to boost sales in the fourth quarter [8][29]. - The second quarter gross margin was stable at 20.1%, with total revenue reaching RMB 30.2 billion, a year-on-year decrease of 5% but a quarter-on-quarter increase of 17% [11][12]. - The report indicates a significant adjustment in revenue and profit forecasts for 2025 and 2026 due to expected declines in sales and operating profit [12][29]. Financial Projections - Revenue projections for 2023 to 2027 are as follows: - 2023: RMB 123,851 million - 2024: RMB 144,460 million - 2025E: RMB 121,217 million (down 16%) - 2026E: RMB 135,335 million (up 12%) - 2027E: RMB 151,527 million (up 12%) [3][9]. - Gross margin is projected to be around 20.2% in 2025, with net profit expected to decline significantly in 2025 before recovering in subsequent years [12][29]. Market Expectations - The report notes that the demand for new energy vehicles in China, particularly in the high-end segment, is expected to drive sales growth for Li Auto. The positive market response to pure electric models is anticipated to enhance average selling prices and gross margins [29][36]. - The company is also expected to invest approximately RMB 6 billion in artificial intelligence this year, which is projected to provide a long-term competitive advantage [8][29].

Investment Rating - The report maintains a "Buy" rating for the company and raises the target price to HKD 77.0, indicating a potential upside of 16% from the current price of HKD 66.5 [2][5][7]. Core Insights - The company's net loss attributable to shareholders for the first half of 2025 was better than expected, with revenue reaching RMB 499 million, a year-on-year increase of 812.1%. Product revenue was RMB 169 million, while collaboration revenue was RMB 329 million, up 502.6% year-on-year [5][7]. - The company is focusing on the commercialization of CM310 and preparing for national medical insurance negotiations, with confidence in multiple indications being included in the insurance scheme [5][7]. - The next-generation core pipeline drug, CM512, is being prioritized for development, showing promising safety and efficacy in preclinical studies [5][7]. Financial Performance - For 1H25, the company reported a net loss of RMB 78.84 million, significantly reduced from RMB 337 million in 1H24, primarily due to better-than-expected collaboration revenue and improved gross margins [5][7]. - The company’s cash position improved to RMB 2.8 billion as of June 30, 2025, up from RMB 2.16 billion at the end of 2024, aided by a successful placement in June [5][7]. - Revenue projections for the upcoming years show significant growth, with expected revenues of RMB 823 million in 2025, RMB 1.5 billion in 2026, and RMB 2.3 billion in 2027, reflecting year-on-year growth rates of 92%, 82%, and 54% respectively [7][9].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of RMB 300, indicating a potential upside of 21% from the current price of RMB 247.08 [1][2]. Core Insights - The company's performance in 1H25 was significantly under pressure, with revenue of RMB 16.7 billion, a year-on-year decrease of 18%, and a net profit of RMB 4.9 billion, down 33% year-on-year. However, there is a clear expectation for revenue recovery starting in 3Q25, with projected positive year-on-year growth [1][8]. - The report anticipates that the recovery in domestic equipment bidding projects will gradually convert into revenue, leading to further revenue growth in 4Q25. The low base effect from the previous year is expected to accelerate revenue and net profit growth in 2026 [1][8]. Financial Performance and Forecast - The company's revenue and net profit forecasts for the upcoming years are as follows: - Revenue: RMB 34.93 billion in 2023, RMB 36.73 billion in 2024, RMB 37.08 billion in 2025E, RMB 45.94 billion in 2026E, and RMB 53.25 billion in 2027E, with year-on-year growth rates of 15.0%, 5.1%, 1.0%, 23.9%, and 15.9% respectively [2][10]. - Net profit: RMB 11.58 billion in 2023, RMB 11.67 billion in 2024, RMB 11.39 billion in 2025E, RMB 14.49 billion in 2026E, and RMB 17.40 billion in 2027E, with year-on-year growth rates of 20.6%, 0.7%, -2.4%, 27.2%, and 20.1% respectively [2][10]. - The report highlights that the company's international revenue is expected to continue to grow, with a projected double-digit growth rate for the second half of 2025 [1][8]. Segment Analysis - Domestic revenue saw a significant decline of 33% in 1H25, primarily due to prolonged weak bidding conditions for equipment, while international revenue grew by 5%, now accounting for 50% of total revenue [8]. - The report notes that the IVD segment experienced a 16% decline in revenue, attributed to price reductions from centralized procurement and a decrease in testing volumes due to policy changes. However, international IVD business showed resilience with a 12% growth [8].

Investment Rating - The report maintains a "Hold" rating for the company with a target price of HKD 17.71, representing a potential upside of 12.0% from the current price of HKD 15.84 [1][5]. Core Insights - The company's revenue and operating profit margins are under pressure, with management indicating that the second half of 2025 will remain challenging. They expect a year-on-year revenue decline in 2025 of mid to high single digits, while operating profit margins are projected to remain flat [5][12]. - The company has experienced a significant decline in liquid milk revenue, down 11.2% in the first half of 2025, which is much greater than its main competitor, Yili, which saw only a 2.1% decline. This suggests a loss of market share for the company [5][12]. - Management's cautious pricing strategy has led to a substantial drop in sales volume, and while they have reduced sales expenses by 8.4%, this may have been a strategic decision to maintain operating profit margins [5][12]. Financial Performance and Forecast - The company's revenue for 2025 is forecasted to be HKD 82.995 billion, a decrease of 6.4% year-on-year. The core net profit is expected to decline by 14.5% to HKD 3.792 billion [7][13]. - The operating profit margin for 2025 is projected to be 8.3%, slightly up from 8.2% in 2024, but the overall financial outlook remains cautious due to market conditions [12][13]. - The report highlights that the company's performance in the first half of 2025 was primarily supported by lower raw milk prices, but this benefit may diminish as prices stabilize [5][12]. Market Context - The report indicates that the industry is facing prolonged challenges, with weak demand and increased competition expected to persist in the short term. This environment is likely to keep the company's sales prices and profit margins under pressure [5][12]. - The management's guidance suggests that the company is still weighing the balance between revenue and profit margins, indicating a potential shift in focus towards maintaining market share in the second half of 2025 [5][12].

Investment Rating - The report maintains a "Buy" rating for the company and raises the target price to HKD 106 [1][11][12] Core Insights - The company achieved a significant increase in net profit, reaching RMB 12.1 billion in 1H25, driven by strong product revenue growth and operational efficiency [1][6][11] - The internationalization strategy is becoming clearer, with the establishment of a clinical development team in the U.S. and ongoing global Phase III trials for key pipeline assets [1][6][11] - The commercialization strategy for the drug Masitide is progressing well, with early sales trends showing promise and a focus on brand building and channel development [1][8][11] Financial Performance - In 1H25, total revenue reached RMB 59.5 billion, a year-on-year increase of 50.6%, with product revenue at RMB 52.3 billion (+37.3% YoY) and licensing revenue at RMB 6.7 billion (+474.2% YoY) [1][6][11] - The company's Non-IFRS net profit improved significantly from a loss of RMB 1.6 billion in 1H24 to a profit of RMB 12.1 billion in 1H25, indicating strong operational efficiency [1][6][11] - The gross margin for products improved to 84.1% in 1H25 from 82.2% in 1H24, while R&D expenses were controlled at RMB 10 billion, down from RMB 14 billion in the previous year [1][6][11] Pipeline and Future Outlook - The company is focusing on the international development of its oncology pipeline, with two key assets, IBI363 and IBI343, entering global Phase III trials [1][6][11] - Upcoming data readouts for Masitide and other pipeline assets are expected in 2H25, which could further enhance the company's market position [1][11][12] - The company aims to achieve five international Phase III MRCT trials by 2030, supported by a strong cash position of USD 2 billion [1][6][11]